Skip to main content
Quest Diagnostics

Tracking Response to Neoadjuvant Systemic Therapy Through Circulating Tumor DNA Analysis in Breast Cancer

Tracking Response to Neoadjuvant Systemic Therapy Through Circulating Tumor DNA Analysis in Breast Cancer

Authors: Marra A, Kim SH, Pareja F, Basili T, Solit DB, Chandarlapaty S, Plitas G, Reis-Filho JS, Weigelt B, King TA, Brown DN

Citation: NPJ Breast Cancer. 2026 Mar 5. doi: 10.1038/s41523-026-00921-4. Online ahead of print.

Specialties: Oncology, Women's health

Related content

Publication
Advanced Minimal Residual Disease Detection Using a Novel Circulating Tumor DNA Assay: A Report of Two Cases
Publication
Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium
Audio Podcast
Enhancing Cancer Treatment Decisions With Ultrasensitive MRD Testing
Test FAQ
Haystack MRD Testing
Publication
Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans
Audio Podcast
Molecular Expression Through the Eyes of the Pathologist and Oncologist

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.